Abdominal obesity in BTBR male mice is associated with peripheral but not hepatic insulin resistance

Jessica B. Flowers,1,2 Angie T. Oler,2 Samuel T. Nadler,2 YounJeong Choi,3 Kathryn L. Schueler,2 Brian S. Yandell,3 Christina M. Kendziorski,4 and Alan D. Attie2

Departments of 1Nutritional Sciences, 2Biochemistry, 3Statistics and Horticulture, and 4Biostatistics and Medical Informatics, University of Wisconsin–Madison, Madison, Wisconsin

Submitted 24 July 2006; accepted in final form 13 November 2006

Flowers JB, Oler AT, Nadler ST, Choi YJ, Schueler KL, Yandell BS, Kendziorski CM, Attie AD. Abdominal obesity in BTBR male mice is associated with peripheral but not hepatic insulin resistance. Am J Physiol Endocrinol Metab 292: E936–E945, 2007. First published November 28, 2006; doi:10.1152/ajpendo.00370.2006.—Insulin resistance is a common feature of obesity. BTBR mice have more fat mass than most other inbred mouse strains. On a chow diet, BTBR mice have elevated insulin levels relative to the C57BL/6J (B6) strain. Male F1 progeny of a B6 × BTBR cross are insulin resistant. Previously, we reported insulin resistance in isolated muscle and in isolated adipocytes in this strain. Whereas the muscle insulin resistance was observed only in male F1 mice, adipocyte insulin resistance was also present in male BTBR mice. We examined in vivo mechanisms of insulin resistance with the hyperinsulinemic euglycemic clamp technique. At 10 wk of age, BTBR and F1 mice had a >30% reduction in whole body glucose disposal primarily due to insulin resistance in heart, soleus muscle, and adipose tissue. The increased adipose tissue mass and decreased muscle mass in BTBR and F1 mice were negatively and positively correlated with whole body glucose disposal, respectively. Genes involved in focal adhesion, actin cytoskeleton, and inflammation were more highly expressed in BTBR and F1 than in B6 adipose tissue. The BTBR and F1 mice have higher levels of testosterone, which may be related to the pathological changes in adipose tissue that lead to systemic insulin resistance. Despite profound peripheral insulin resistance, BTBR and F1 mice retained hepatic insulin sensitivity. These studies reveal a genetic difference in body composition that correlates with large differences in peripheral insulin sensitivity.

INSULIN RESISTANCE IS A PREDIABETIC SYNDROME (8, 49, 63, 74). Over 40 million Americans are estimated to be insulin resistant (3). Not all individuals with impaired insulin sensitivity will go on to develop type 2 diabetes; however, increased morbidity and mortality already exist in insulin-resistant individuals (23, 29, 38, 39).

The distribution of excess fat may be the most important determinant of overall risk for complications of insulin resistance such as cardiovascular disease (67). The body mass index is widely used for assessing risk of insulin resistance and its common comorbidities (2, 18) but fails to account for individuals who are heavy due to musculature or those who have a normal body weight but still have excess abdominal adiposity. Excess abdominal fat is associated with a much greater risk of morbidity and mortality than is excess subcutaneous fat (60, 69, 79). It is estimated that 13–18% of individuals with normal body mass index have significant risk factors for diabetes and cardiovascular disease (17, 42). Factors such as sex and race appear to influence fat distribution and also the threshold for which excess adipose tissue results in insulin resistance and cardiovascular complications (19, 30, 52, 53, 56). The mechanisms linking fat localization and pathogenicity remain poorly understood. Finding models to adequately represent the spectrum of weight distribution and associated risks will help us to understand this complex process.

Inbred mouse strains replicate much of the genetic and sex variation in human insulin sensitivity. We have focused on the BTBR strain, which replicates many features of insulin resistance found in humans with excess visceral adiposity. Leptin-deficient BTBR ob/ob mice are a particularly useful animal model for studying obesity-related diabetes. Unlike the B6 leptin−/− mice, which develop only a moderate hyperglycemia, BTBR leptin−/− mice become severely diabetic (73). Human studies have demonstrated that, prior to the onset of hyperglycemia, insulin resistance is an important predictor of diabetes susceptibility in relatives of type 2 diabetes (26, 28, 31). Therefore, by examining differences between BTBR and B6 lean mice, we may determine specific factors that confer increased diabetes susceptibility prior to the onset of disease.

Our laboratory has found that, even in the absence of the obesity imposed by leptin deficiency, BTBR mice have elevated insulin levels relative to the B6 mouse strain (73). Male F1 progeny of a B6 × BTBR cross (F1) have increased abdominal obesity, hyperinsulinemia, hyperglycemia, and hypercholesterolemia (65). These phenotypes are present in association with impaired glucose tolerance and reduced insulin-stimulated glucose uptake into isolated muscles (65). Further characterization of the insulin-resistant phenotype of F1 male mice revealed a blunted insulin response in isolated adipocytes (57). Adipocyte insulin resistance is also present in BTBR males (12). In contrast, muscle insulin resistance was observed only in F1 males (65). Consistent with other studies demonstrating protection from insulin resistance and diabetes in female rodents (34, 47, 51), neither adipocyte nor muscle insulin resistance was observed in female mice of either strain (12, 57, 65).

Tissue-specific deletion of the GLUT4 glucose transporter or the insulin receptor has revealed that defects in individual tissues can have systemic consequences (54). Most surprising was the finding that loss of glucose sensing in adipose tissue could result in insulin resistance in muscle (1). We hypothe-
sized that muscle insulin resistance in BTBR mice may be revealed by in vivo studies of insulin sensitivity.

To determine the interplay among tissues contributing to insulin resistance in our model, we performed hyperinsulinemic euglycemic clamp experiments. We determined that BTBR and F1 mice exhibit insulin resistance primarily in heart, soleus muscle, and adipose tissue. In contrast, the liver showed normal insulin sensitivity. Thus, BTBR and F1 male mice present a model of abdominal obesity associated with peripheral but not hepatic insulin resistance.

METHODS

Animals. BTBR T+ tf/J (BTBR) and C57BL/6d (B6) animals were purchased from the Jackson Laboratory (Bar Harbor, ME) and bred at the University of Wisconsin–Madison. F1 mice were generated by breeding a B6 male to a BTBR female. Mice were housed on a 12:12-h light-dark cycle, lights on at 0600. Mice had free access to a chow diet of roughly 6% fat (by mass, Purina 5008) and water, except for during fasts and during the clamp procedure. Research protocols were approved by the University of Wisconsin Institutional Animal Care and Use Committee.

Surgery. Four to six days prior to the clamp, mice were catheterized through the right jugular vein. Surgeries were carried out under isoflurane anesthesia. A Silastic catheter (0.025 in. OD; VWR International, West Chester, PA) filled with saline was inserted via a right lateral neck incision, advanced into the superior vena cava via the right internal jugular vein, and sutured in place. The catheter was then knotted at the distal end, tunneled subcutaneously, exteriorized at the dorsal cervical midline, and then further tunneled subcutaneously. A silk suture was fastened around the catheter at the neck site. On the day of the clamp, the catheter was externalized by pulling the suture through the dorsal cervical incision site.

Hyperinsulinemic euglycemic clamp. Mice were brought to the experimental room and fasted at 1000. At 1330, basal mice were placed in broom-style restrainers, and catheters were externalized. Tails were anesthetized with lidocaine and prilocaine cream (2.5%/2.5%; E. Fougera, Atlanta, Melville, NY), and mice were allowed to acclimate to their confinement. At 1400, the tail was clipped, and the catheter was connected to a pump (model 102; CMA Mico dialysis, Solna, Sweden). HPLC-purified [3-3H]glucose (PerkinElmer Life Sciences, Boston, MA) was infused at 0.055 μCi/min in saline at a rate of 3.3 ml/min. Blood (30 μl) was collected by gently massaging the tail at 90, 100, and 110 min for determination of blood glucose and plasma specific activity. At 1530, clamp mice were placed in broom-style restrainers and catheters were externalized. Tails were anesthetized, and mice were allowed to acclimate to their confinement. At 1600, the tail was clipped, and the catheter was connected to a pump. A saline solution was infused at 3.3 μl/min containing human insulin (2.5 μU/kg·min·1 Humulfin R; Eli Lilly, Indianapolis, IN) along with [3-3H]glucose (0.1,375 μCi/min; PerkinElmer Life Sciences) and 2-deoxy-2-[1-14C]glucose (0.825 μCi/min; PerkinElmer Life Sciences) for the determination of whole body glucose fluxes and tissue glucose uptake, respectively. Dextrose solution (20%; Phoenix Pharmaceuticals, St. Joseph, MO) was infused at a variable rate to maintain blood glucose at ~100 mg/dL. Blood (~8 μl) was collected initially and every 10 min throughout the 2-h infusion for determination of glucose concentration. Additional blood (20 μl) was collected at 70, 80, 90, 100, 110, and 120 min for determination of specific activity. Following the last tail bleed, mice were disconnected from the pump and killed with an isoflurane overdose. Following respiratory arrest, a heart puncture was performed for blood collection and heart, liver, epididymal white adipose tissue (EpiWAT), soleus muscle, and quadriceps muscle were removed and immediately frozen in liquid nitrogen and then transferred to a −80°C freezer.

Assays. Glucose concentration was analyzed using a hand-held glucose monitor (Prestige IQ; Home Diagnostics, Fort Lauderdale, FL). Plasma glucose was estimated as blood glucose multiplied by 1.12 as referenced by the glucometer manufacturer (Home Diagnostics). Plasma insulin concentrations were measured by radioimmunoassay kit (Linco Research, St. Charles, MO). Plasma testosterone levels were measured using the DSL-4000 ACTIVE testosterone radioimmunoassay kit (Diagnostic Systems Laboratories, Webster, TX). Plasma concentrations of [3-3H]glucose, 2-deoxy-2-[1-14C]glucose (2-DG), and [3H]H2O were determined after deproteinization of plasma samples with Ba(OH)2 and ZnSO4, as previously described (45). For the determination of tissue 2-deoxy-2-[1-14C]glucose-6-phosphate (2-DG-6-P) content, tissues were homogenized, and the supernatants were subjected to an ion exchange column (Poly-Prep 731–6211; Bio-Rad Laboratories, Hercules, CA) to separate 2-DG-6-P from 2-DG (45). 3H and 14C were counted in Bio-Safe II scintillation fluid (Research Products, Mount Prospect, IL) on a scintillation counter (PerkinElmer, Shelton, CT).

Calculations. Basal hepatic glucose output was calculated as the ratio of the [3-3H]glucose infusion rate (dpm/min) to the specific activity of plasma glucose (dpm/mg) at 90, 100, and 110 min. Clamp whole body glucose uptake was calculated as the ratio of [3-3H]glucose infusion rate (dpm/min) to the specific activity of plasma glucose (mean of the 90- to 120-min samples). Because 3H on the C-3 position of glucose is lost to water during glycolysis, the rate of glycolysis can be determined from the rate of increase in plasma [3H]H2O determined by linear regression using the 70- to 120-min points (66). Plasma [3H]H2O was calculated as the difference between nondried and dried plasma 3H counts. Plasma was dried under nitrogen gas. For calculating the rate of whole body glycolysis, the body was assumed to be 65% fat and the plasma 93% water (66). Clamp hepatic glucose output was determined by subtracting the average steady-state glucose infusion rate in the last 40 min of the clamp from the whole body glucose uptake (45). The rate of whole body glycogen synthesis was estimated by subtracting the rate of glycolysis from whole body glucose disposal (66). Muscle and white adipose tissue glucose uptake were calculated from the average plasma 2-DG specific activity (70- to 120-min points) and tissue 2-DG-6-P content. All measurements were made when steady-state conditions were achieved.

Real-time quantitative PCR. RNA was isolated from individual livers by use of RNeasy minicolumns with on-column DNase digestion (Qiagen, Valencia, CA). First-strand cDNA was synthesized from 1 μg of total liver RNA, or 0.3 μg of adipose tissue RNA using SuperScript III Reverse Transcriptase primed with a mixture of oligo(dT) and random hexamers (Invitrogen Life Sciences, Carlsbad, CA). Reactions lacking the reverse transcriptase served as control for amplification of genomic DNA. Liver reactions were performed on an ABI GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, CA) and carried out in a 25-μl volume of 1× SYBR Green PCR Core Reagents (Sigma-Aldrich, St. Louis, MO) containing cDNA template from 10 ng of total RNA and 6 pmol primers. Adipose tissue reactions were performed on an ABI GeneAmp 7500 Sequence Detection System (Applied Biosystems) and carried out in a 20-μl volume of 1× ABI SYBR Green PCR Master Mix containing cDNA template from 3 ng of total RNA and 6 pmol primers. We determined the cycle at which the abundance of the accumulated PCR product crossed a specific threshold, the threshold cycle (Ct), for each reaction. For hepatic measurements, differences in Ct values between β-actin (M12481) and phosphoenolpyruvate carboxykinase (PEPKC, NM_011044) or G-6-Pase (NM_008061) were calculated for each individual, and in the adipose tissue acidic ribosomal ribosomal phosphoprotein P0 (Arnp; NM_007475) was used as a normalization control. Gene-specific primers were designed for standard RT-PCR cycling parameters using Primer Express software v. 1.0–2.0 (Applied Biosystems). Specificity was determined by observation of a single dissociation peak and by aligning primers in the University of California-Santa Cruz Mouse Genome Browser (genome.ucsc.edu, February 2006).
statistically significant difference by one-way ANOVA with Tukey post test, representing means ± SE of 6–7 mice per group. Different letters designate a statistically significant difference by one-way ANOVA with Tukey post test, P < 0.05.

**RESULTS**

Whole body glucose metabolism. To determine the effects of strain background on whole body glucose metabolism, we performed hyperinsulinemic euglycemic clamp experiments. Because the B6 strain has a lower basal insulin level than the BTBR or the F1 mice, we chose to expose the three groups of mice to the same amount of insulin to measure the response to an equal insulin dose rather than try to achieve the same steady-state insulin level. Indeed, the insulin infusion raised insulin levels by about the same amount in all three mouse groups. The alternative would have been to match all three groups for the steady-state insulin level. This would have required us to deliver a different amount of insulin to the B6 mice than to the other two groups.

The rate of glucose infusion needed to maintain euglycemia at ~100 mg/dl was highest in B6 mice, tended to be lower in BTBR mice (P = 0.12), and was significantly lower in F1 mice than in either parental strain (22.1 ± 2.8 and 15.8 ± 1.4 vs. 6.9 ± 1.6 mg·kg⁻¹·min⁻¹, P < 0.001 and P < 0.05, respectively; Fig. 1A). Compared with B6 mice, glucose disposal in BTBR and F1 mice was reduced by 34 and 43%, respectively (Fig. 1B). Two processes contribute to glucose disposal: glycogen synthesis and glycolysis. Glycolysis, which accounted for the majority of glucose disposal, was reduced by 40% in BTBR and F1 mice (Fig. 1C). Glycogen synthesis was slightly lower in BTBR mice and was significantly lower in F1 mice than in B6 mice (Fig. 1D). Thus, BTBR and F1 mice have significantly reduced glucose disposal, primarily due to a defect in glycolysis.

**Body composition effects on glucose metabolism.** Despite reduced body weight, B6 mice disposed of ~20% more total glucose than either BTBR or F1 mice. To determine the tissues responsible for the decreased whole body glucose disposal in BTBR and F1 mice, we measured the rate of 2-DG uptake in individual tissues. Insulin-stimulated glucose uptake in heart was decreased by over 50% in BTBR and F1 mice (Fig. 2A). Glucose uptake in soleus muscle was reduced by 56% in BTBR and 72% in F1 mice, respectively (Fig. 2B). Insulin resistance in the heart and soleus muscles, which are composed mainly of red or oxidative muscle fibers, is consistent with previous work demonstrating that red muscle fibers are more susceptible to insulin resistance than white muscle fibers (10, 22, 32, 33). The quadriceps muscle is primarily composed of white muscle fibers but does contain red muscle fibers. In contrast to heart and soleus muscle, quadriceps muscle glucose uptake was increased approximately twofold in BTBR compared with B6 and F1 mice (Fig. 2C). The increase in glucose uptake in quadriceps muscle of BTBR mice suggests altered quadriceps muscle fiber composition or compensation for reduced disposal in the more oxidative heart and soleus muscles.

**Microarray data analysis.** To examine the changes in gene expression among lean groups of animals, we chose to reanalyze murine 11K microarray data previously obtained by our laboratory (data available through NCBI GEO; GSE2952). As described previously, epididymal fat pads were isolated from 14-wk-old mice after a 4-h fast (58). RNA was isolated and cDNA prepared from equal amounts of RNA pooled from at least four animals. In the new analysis, quantitative expression measurements were analyzed, and statistically significant differential expression was determined using the empirical Bayes methodology EBarrays (43, 59), which are implemented in R, a publicly available statistical analysis environment (75). For each comparison, we identified a list of differentially expressed transcripts with false discovery rate (FDR) at 5%.

**Statistics.** All data are represented as means ± SE. Comparisons among three groups were made using one-way ANOVA, and when significance was observed, post hoc Tukey tests were performed using GraphPad Prism v. 4.02 for Windows (GraphPad Software, San Diego, CA). Comparisons of two groups were done using an unpaired Student’s t-test in GraphPad or Microsoft Excel (© 2002). Regression analyses were performed in Systat v. 8.0 (SPSS). Heat plots of regression coefficients were generated in R (75). Statistical significance was set at P < 0.05.

**Fig. 1.** In vivo whole body glucose flux during hyperinsulinemic euglycemic clamp studies in awake, male mice at 10 wk of age. A: glucose infusion. B: whole body glucose disposal. C: glycolysis. D: glycogen synthesis. Data represent means ± SE of 6–7 mice per group. Different letters designate a statistically significant difference by one-way ANOVA with Tukey post test, P < 0.05.
In WAT, glucose uptake was slightly reduced in BTBR mice but reduced by 58% in F1 mice (Fig. 2D). Although our previous reports noted profound insulin resistance in isolated adipocytes (12, 57), these results demonstrate that, when in direct competition with more metabolically active tissues, adipose tissue differences are dampened.

In addition to altered glucose uptake in various tissues, we observed strain differences in tissue mass. Relative to B6 mice, BTBR and F1 mice had a 50 and 100% increase, respectively, in EpiWAT mass and, surprisingly, a 30% decrease in quadriceps and soleus muscle mass (Table 1 and Fig. 2E). To fully assess the contribution of each tissue to total glucose disposal, we calculated the product of the tissue mass and the 2-DG uptake measurement. With this calculation, we have almost completely captured the strain differences in whole body glucose disposal, with BTBR having ~80% and F1 70% of the B6 glucose disposal by four tissues (Fig. 2F). The increased adipose mass in BTBR and F1 mice compensates for reduced adipose glucose disposal but is insufficient to overcome the differences in muscle mass and glucose disposal. Although quadriceps and soleus muscle mass was positively correlated with whole body glucose disposal (GDISP), body weight and WAT mass were negatively correlated with GDISP (Table 1). Heart and liver mass did not show a correlation with GDISP. These correlation trends were similar for rates of glycolysis and glycogen synthesis (Table 1). Therefore, increased adipose tissue can predict reduced glucose disposal, whereas increased muscle can predict enhanced glucose disposal.

Adipose tissue gene expression. Insulin resistance originating in adipose tissue may affect all insulin target tissues (1). Muscle insulin resistance in BTBR mice was observed only in vivo, whereas adipose tissue has in vitro differences in insulin sensitivity, suggesting that the defect in adipose tissue is a primary effect and the muscle changes might be secondary.

We were interested in identifying the transcripts whose abundance changed with modest differences in adiposity and insulin sensitivity. We (58) previously reported on adipose tissue transcripts whose abundance changed in mice when they became severely obese with the leptinob/ob mutation. Thus, we reanalyzed our data and identified changes in lean male mice. After RMA normalization of the data, we used the EBarrays algorithm to identify genes that were differentially expressed. Using the KEGG and Biocarta pathway tools, available through Web-based Gene Set Analysis Toolkit (85) (bioinfo.vanderbilt.edu/webgestalt), we selected genes with known pathway enrichment and confirmed these by RT-PCR using adipose tissue cDNA from animals subjected to the clamp procedure. We confirmed 15 genes as being significantly differentially expressed (Table 2). Five additional genes that were predicted to be decreased in B6 (Cek, Cebph, Egf, Ifitm3, Pla2g12a) and four that were predicted to be increased (Akr1b7, Cd52, Il2ra, Tnfrsf8) were tested but not confirmed. It is possible that these genes may be false positives. However, with ~100 genes predicted to be different, we would expect, at most, five genes to be false positives. A more plausible explanation is that some of these genes may be differentially regulated during fasting vs. clamp conditions.

Several of the differentially expressed genes are related to cytoskeletal structure and function (Acta, Actb, Diap1, Rhoa). Insulin signaling induces cytoskeletal changes that are necessary for GLUT4 movement to the cell surface (27, 77). Cytoskeletal changes also occur to accommodate the expansion of adipocytes (70, 71). Increased leptin gene expression in BTBR and F1 mice is a good indicator of enlarged adipocytes (20, 50).

Filamin (Flha) as well as several of the cytoskeletal genes (Actb, Diap1, Rhoa) are involved in focal adhesion. Formation of focal adhesions and remodeling of actin are important steps in adipocyte hyperplasia (6). Focal adhesions are cell membrane structures that contain several signaling molecules involved in the regulation of cell growth, including mitogen-activated protein kinases (MAPK) (68).

Control of signaling through MAPK pathways or the insulin-signaling pathway occurs through a series of phosphorylation-dephosphorylation events. Whereas altered phosphorylation of MAPK pathway components can affect proliferation of adipose tissue, phosphorylation of the insulin receptor regulates insulin sensitivity. Consistent with the microarray results, we found three phosphatases (Ppp2r4, Ppp6c, and Ptp1r) to be upregulated in BTBR and F1 mice (Table 2). Although these phosphatases do not have a known role in adipose tissue, their impacts on intracellular signaling warrant further investigation, as their expression levels were highly negatively correlated with whole body glucose disposal (Table 2 and Fig. 3).

Increased adiposity has previously been associated with increased inflammation (64, 80, 81, 83). Consistent with increased inflammation in adipose tissue from BTBR and F1 mice, several genes involved in inflammatory pathways were differentially expressed (Cfll, Fos, H2ab1, Pir.s (Pirata, Piraba, Pirb, and Pirb/Lilrb), Ptg52, and Syk). In addition to promoting insulin resistance (35, 36, 62, 78), inflammatory factors can affect muscle mass by inhibiting de novo protein synthesis or by promoting muscle breakdown (11, 48). This predicts that adipose tissue expression of inflammatory genes would be

### Table 1. Body composition and correlation with glucose metabolism

<table>
<thead>
<tr>
<th>Tissue</th>
<th>B6</th>
<th>BTBR</th>
<th>F1</th>
<th>GDISP</th>
<th>Glycolysis</th>
<th>Glycogen</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight, g</td>
<td>26.3±0.6*</td>
<td>32.8±0.4†</td>
<td>36.5±1.0†</td>
<td>−8.50</td>
<td>−0.749</td>
<td>−0.511</td>
</tr>
<tr>
<td>Liver, %BW</td>
<td>3.8±0.08</td>
<td>3.90±0.23</td>
<td>3.70±0.05</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>EpiWAT, %BW</td>
<td>1.26±0.12*</td>
<td>1.82±0.13†</td>
<td>2.55±0.11†</td>
<td>−0.704</td>
<td>−0.504</td>
<td>−0.623</td>
</tr>
<tr>
<td>Quadriceps, %BW</td>
<td>0.685±0.018*</td>
<td>0.448±0.023†</td>
<td>0.465±0.029†</td>
<td>NS</td>
<td>0.677</td>
<td>0.567</td>
</tr>
<tr>
<td>Heart, %BW</td>
<td>0.507±0.037</td>
<td>0.455±0.010</td>
<td>0.430±0.009</td>
<td>NS</td>
<td>NS</td>
<td>0.511</td>
</tr>
<tr>
<td>Soleus, %BW</td>
<td>0.029±0.002*</td>
<td>0.020±0.001†</td>
<td>0.022±0.001†</td>
<td>0.788</td>
<td>0.789</td>
<td>NS</td>
</tr>
</tbody>
</table>

Values are means ± SE of 6–7 mice per group. Tissue weights are from 10-wk-old male mice and are normalized to body weight (BW). Different symbols designate a statistically significant difference by one-way ANOVA with Tukey’s post test, P < 0.05. Nos, sharing the same symbols are not significantly different. Pearson correlation coefficients for significant correlations (P < 0.05) are shown for whole body glucose disposal (GDISP), rate of glycolysis, and rate of glycogen synthesis.
Table 2. Gene expression changes in adipose tissue correlated with glucose disposal, muscle mass, and testosterone

<table>
<thead>
<tr>
<th>Accession No.</th>
<th>Symbol</th>
<th>Description</th>
<th>Fold</th>
<th>P Value</th>
<th>GDISP Corr</th>
<th>P Value</th>
<th>Quad Corr</th>
<th>P Value</th>
<th>Sol Corr</th>
<th>P Value</th>
<th>Testosterone P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>M12481</td>
<td>Actb***</td>
<td>Actin, beta, cytoplasmic</td>
<td>5.4</td>
<td>0.000</td>
<td>−0.850</td>
<td>0.000</td>
<td>−0.850</td>
<td>0.000</td>
<td>−0.807</td>
<td>0.000</td>
<td>0.588</td>
</tr>
<tr>
<td>BC064800</td>
<td>Acta2*</td>
<td>Actin, alpha 2, smooth muscle, aorta</td>
<td>2.7</td>
<td>0.001</td>
<td>−0.675</td>
<td>0.001</td>
<td>−0.782</td>
<td>0.000</td>
<td>−0.618</td>
<td>0.002</td>
<td>0.369</td>
</tr>
<tr>
<td>XM_289920</td>
<td>Flna**</td>
<td>Filamin, alpha</td>
<td>2.2</td>
<td>0.006</td>
<td>−0.627</td>
<td>0.003</td>
<td>−0.700</td>
<td>0.001</td>
<td>−0.679</td>
<td>0.000</td>
<td>0.279</td>
</tr>
<tr>
<td>NM_008848</td>
<td>Ppp6c</td>
<td>Protein phosphatase 6, catalytic subunit</td>
<td>2.2</td>
<td>0.000</td>
<td>−0.741</td>
<td>0.000</td>
<td>−0.710</td>
<td>0.000</td>
<td>−0.650</td>
<td>0.002</td>
<td>0.577</td>
</tr>
<tr>
<td>NM_016802</td>
<td>Rhoa***</td>
<td>Ras homolog gene family, member A</td>
<td>1.7</td>
<td>0.002</td>
<td>−0.614</td>
<td>0.004</td>
<td>−0.342</td>
<td>0.140</td>
<td>−0.428</td>
<td>0.059</td>
<td>0.305</td>
</tr>
</tbody>
</table>

**Cytoskeletal* and focal adhesion**

<table>
<thead>
<tr>
<th>Accession No.</th>
<th>Symbol</th>
<th>Description</th>
<th>Fold</th>
<th>P Value</th>
<th>GDISP Corr</th>
<th>P Value</th>
<th>Quad Corr</th>
<th>P Value</th>
<th>Sol Corr</th>
<th>P Value</th>
<th>Testosterone P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>NM_010234</td>
<td>Fos</td>
<td>FBJ osteosarcoma oncogene</td>
<td>4.2</td>
<td>0.027</td>
<td>−0.340</td>
<td>0.143</td>
<td>−0.376</td>
<td>0.103</td>
<td>−0.342</td>
<td>0.182</td>
<td>0.388</td>
</tr>
<tr>
<td>M64291</td>
<td>Ptgs2</td>
<td>Prostaglandin-endoperoxide synthase 2</td>
<td>2.7</td>
<td>0.039</td>
<td>−0.436</td>
<td>0.062</td>
<td>−0.512</td>
<td>0.025</td>
<td>−0.514</td>
<td>0.024</td>
<td>0.522</td>
</tr>
<tr>
<td>NM_011518</td>
<td>Syk</td>
<td>Spleen tyrosine kinase</td>
<td>2.5</td>
<td>0.005</td>
<td>−0.574</td>
<td>0.008</td>
<td>−0.715</td>
<td>0.000</td>
<td>−0.624</td>
<td>0.003</td>
<td>0.630</td>
</tr>
<tr>
<td>NM_020765</td>
<td>Clur</td>
<td>CASP8 and FADD-like apoptosis regulator</td>
<td>1.9</td>
<td>0.001</td>
<td>−0.730</td>
<td>0.000</td>
<td>−0.647</td>
<td>0.003</td>
<td>−0.610</td>
<td>0.001</td>
<td>0.587</td>
</tr>
<tr>
<td>NM_010379</td>
<td>H2ab1</td>
<td>Histocompatibility 2, class II antigen A, beta 1</td>
<td>1.5</td>
<td>0.013</td>
<td>−0.412</td>
<td>0.071</td>
<td>−0.339</td>
<td>0.143</td>
<td>−0.312</td>
<td>0.120</td>
<td>0.491</td>
</tr>
</tbody>
</table>

**Inflammation**

<table>
<thead>
<tr>
<th>Accession No.</th>
<th>Symbol</th>
<th>Description</th>
<th>Fold</th>
<th>P Value</th>
<th>GDISP Corr</th>
<th>P Value</th>
<th>Quad Corr</th>
<th>P Value</th>
<th>Sol Corr</th>
<th>P Value</th>
<th>Testosterone P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>NM_011218</td>
<td>Pptrs</td>
<td>Protein tyrosine phosphatase 2A, regulatory subunit B (PR53)</td>
<td>4.5</td>
<td>0.000</td>
<td>−0.832</td>
<td>0.000</td>
<td>−0.839</td>
<td>0.000</td>
<td>−0.843</td>
<td>0.000</td>
<td>0.589</td>
</tr>
<tr>
<td>NM_138748</td>
<td>Ppp2r4</td>
<td>Protein phosphatase 2A, regulatory subunit B (PR53)</td>
<td>1.7</td>
<td>0.001</td>
<td>−0.701</td>
<td>0.001</td>
<td>−0.662</td>
<td>0.002</td>
<td>−0.651</td>
<td>0.000</td>
<td>0.510</td>
</tr>
<tr>
<td>NM_024209</td>
<td>Ppp6c</td>
<td>Protein phosphatase 6, catalytic subunit</td>
<td>1.5</td>
<td>0.003</td>
<td>−0.689</td>
<td>0.001</td>
<td>−0.650</td>
<td>0.002</td>
<td>−0.710</td>
<td>0.001</td>
<td>0.390</td>
</tr>
<tr>
<td>U18812</td>
<td>Lep</td>
<td>Leptin</td>
<td>6.2</td>
<td>0.000</td>
<td>−0.852</td>
<td>0.000</td>
<td>−0.779</td>
<td>0.000</td>
<td>−0.730</td>
<td>0.000</td>
<td>0.519</td>
</tr>
</tbody>
</table>

Expression measurements were determined for 6–7 mice per genotype. Individual values were normalized to Arbp and then expressed relative to B6 mice. Fold change represents the average of BTBR and F1 animals. Corr, Pearson correlations between individual expression values and GDISP; quadriceps muscle (Quad), soleus muscle (Sol), and plasma testosterone values. ***NM_008848, NM_011093, NM_011095.

negatively correlated with muscle mass. As indicated in Table 2 and Fig. 3, gene expression changes in adipose tissue were negatively correlated with muscle weight.

**Testosterone and insulin resistance.** Determining whether hyperandrogenemia promotes or protects against insulin resistance has been a complicated issue. Whereas hyperandrogenemia and insulin resistance are common features of polycystic ovary syndrome (16, 61), hypoandrogenemia has also been associated with increased insulin resistance in men (41, 61). Whether hyperandrogenemia is the cause or the consequence of insulin resistance remains undetermined. Testosterone could directly induce insulin resistance by inhibiting secretion of adiponectin (82). However, there is also evidence suggesting that hyperinsulinemia drives androgen production (5). Irrespective of the cause, whether testosterone levels could drive inflammation (4, 25). Given that adipocyte and muscle insulin resistance was observed only in male mice, we determined whether these defects were related to differences in testosterone levels. Testosterone levels tended to be higher in F1 mice and were significantly higher in BTBR mice compared with B6 mice (0.41 ± 0.04 and 0.46 ± 0.05 vs. 0.28 ± 0.04 ng/ml, P = 0.14 and P = 0.04, respectively). Consistent with induced androgen signaling (24), there was a significant positive correlation between plasma testosterone concentration and Cflar/c-FLIP mRNA expression (R = 0.587, P = 0.008; Table 2). Testosterone levels were also positively correlated with other differentially expressed genes and negatively correlated with whole body glucose disposal (Table 2 and Fig. 3).

**Plasma chemistry and hepatic insulin sensitivity.** During the clamp experiments, we infused insulin to measure the responsiveness of the liver. Despite whole body insulin resistance, BTBR and F1 mice exhibited normal hepatic insulin sensitivity. This was illustrated by a greater than 50% reduction in hepatic glucose output (HGO) under conditions of physiological hyperinsulinemia (Fig. 4A). Somewhat surprisingly, B6 mice exhibited higher basal/fasting HGO than BTBR or F1 mice (Fig. 4A). However, fasting plasma insulin was ~80% lower in B6 mice (Table 3). Therefore, this seemingly predi-
abetic hyperglycemic phenotype seen in B6 mice is likely due to the differences in fasting insulin. Insulin secretion defects in B6 mice have been reported (76) and are predominantly due to a mutation in nicotinamide nucleotide transhydrogenase (21). Following insulin infusion, when insulin levels were similarly raised in all groups by ~0.5 ng/ml (Table 3), HGO was not different among the strains of mice (Fig. 4A), a result indicating that the fasting hyperglycemia observed in B6 mice was not due to hepatic insulin resistance.

As a further assessment of hepatic insulin sensitivity, we measured the expression of gluconeogenic enzymes, PEPCK and G6Pase. PEPCK and G6Pase are regulated at the transcriptional level by insulin and are important determinants of hepatic glucose output. We determined that expression of PEPCK and G6Pase were about twofold higher in B6 mice under fasting conditions when B6 mice were hypoinsulinemic relative to BTBR and F1 mice (Fig. 4, B and C). However, following insulin infusion, expression levels of PEPCK and G6Pase were reduced in B6 mice and no longer significantly different from BTBR and F1 mice (Figs. 4, B and C). It is possible that the reduction of glucose output was a result of a change in the activity of these enzymes. Thus, the levels of expression of these two insulin-responsive genes support the conclusion that there are no strain differences in hepatic insulin sensitivity.

**DISCUSSION**

Obesity and associated insulin resistance are a growing worldwide epidemic. The mechanisms regulating fat localiza-
The finding of insulin resistance in BTBR soleus muscle is novel; previous in vitro studies did not identify a defect in this tissue. Muscle is the major site of insulin stimulated glucose disposal. Yet mice with selective loss of the insulin receptor in muscle (MIRKO) do not develop hyperglycemia (44). MIRKO mice have a compensatory increase in glucose uptake into adipose tissue, resulting in increased fat mass. In the present study, we observed insulin resistance in muscle without a compensatory increase in adipose tissue glucose uptake, suggesting that the obesity phenotype we observed is not a consequence of adipose tissue compensation for muscle insulin resistance. Furthermore, BTBR mice exhibit insulin resistance isolated adipocytes, whereas muscle insulin resistance was observed only in vivo, suggesting that muscle changes might be secondary to the changes in adipose tissue.

BTBR mice exhibit differences in adipocyte insulin sensitivity in vitro (12). Fat replacement studies in adipocyte-deficient mice revealed that adipose tissue is an important endocrine organ and not merely a storage site for excess energy (14). Reduced muscle glucose uptake was observed only in vivo and not in isolated muscle strips, suggesting that insulin-resistant adipose tissue produces a circulating factor capable of inhibiting muscle glucose uptake. Adipokines secreted from adipose tissue can either enhance (leptin, adiponectin) or impair insulin signaling in muscle, fat, and liver, resulting in hyperinsulinemia and hyperglycemia (55).

In addition to adipokines, estrogens and androgens may mediate changes in insulin sensitivity and inflammation (4, 13). Testosterone can inhibit secretion of adiponectin, an insulin-sensitizing molecule secreted from adipose tissue (82). Indeed, elevations in testosterone in BTBR and F1 mice are negatively correlated with whole body glucose disposal ($R = -0.493$, $P < 0.05$). Testosterone directly stimulates TNF-α production in macrophages (4). This finding provides a possible explanation for the pleotropic effects mediated by testosterone: inflammatory responses and alterations in insulin sensitivity.

TNF-α was originally named cachectin, as it was found to induce cachexia (7), a wasting syndrome associated with severe trauma, infection, and cancer. Whereas cachexia is a severe pathological state, milder forms of wasting may be associated with obesity and insulin resistance. The low-grade chronic inflammation associated with increased adiposity may affect muscle protein synthesis or catabolism (11, 48). This provides a possible mechanism for the reduced muscle mass seen in BTBR and F1 mice. Indeed, we saw significant negative correlations between adipose inflammatory gene expression and muscle mass. Thus, reduced glucose disposal may be caused by inflammatory molecules inducing insulin resistance and reducing relative muscle mass. Therefore, targeting inflammation early and adding exercise or strength training to preserve muscle mass and function in prediabetes may be of critical importance in preventing progression to type 2 diabetes.

In summary, we determined that several inflammatory genes are induced in adipose tissue from insulin-resistant male mice. Consistent with the idea that inflammatory factors secreted from adipose tissue induce systemic insulin resistance, we found an association between inflammatory gene expression changes in adipose tissue and glucose uptake in heart and soleus muscle. Additionally, expression of inflammatory genes in adipose tissue negatively correlated with muscle mass. Elevations in testosterone in BTBR and F1 mice appear related to the pathological changes in adipose tissue and systemic insulin resistance. Further characterization of the insulin resistance in BTBR and F1 lean mice revealed that, despite significant peripheral insulin resistance, these mice maintain hepatic insulin sensitivity. Most adipokines, including TNF-α and adiponectin, affect hepatic glucose output (15, 46). Hence, it was surprising to find intact hepatic insulin sensitivity in BTBR and F1 mice. Further studies of BTBR and F1 mice may reveal important factors capable of preserving hepatic insulin sensitivity in individuals with obesity and insulin resistance.

**Acknowledgments**

We thank Mary Rabaglia, Susanne Clee, and Hong Lan for technical assistance and intellectual contributions. We thank members of Gerald Schuman’s lab for help with experimental design and members of Derry Roopenian’s lab for help with RT-PCR primer design. We also thank Scott Hubbard-Van Stelle at the University of Wisconsin–Madison Research Animal Resources Center and various members of Denise M. Ney’s lab for guidance on surgical techniques.

---

**Table 3. Metabolic parameters in basal and clamp mice**

<table>
<thead>
<tr>
<th></th>
<th>B6</th>
<th>BTBR</th>
<th>F1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Plasma glucose, mg/dl</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basal</td>
<td>221 ± 11*</td>
<td>145 ± 14*</td>
<td>193 ± 10*</td>
</tr>
<tr>
<td>Clamp</td>
<td>108 ± 1</td>
<td>105 ± 5</td>
<td>111 ± 8</td>
</tr>
<tr>
<td><strong>Plasma insulin, ng/ml</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basal</td>
<td>0.21 ± 0.05*</td>
<td>0.91 ± 0.15†</td>
<td>0.99 ± 0.17†</td>
</tr>
<tr>
<td>Clamp</td>
<td>0.63 ± 0.08*</td>
<td>1.49 ± 0.33†</td>
<td>1.51 ± 0.24†</td>
</tr>
</tbody>
</table>

Values are means ± SE of 6–8 mice per group. Different symbols designate a statistically significant difference by one-way ANOVA with Tukey’s post test. Glucose values are the average of the last 3 time points (basal) and last 4 time points (clamp). Insulin values were obtained from plasma following heart puncture.
REFERENCES

16. Coviello AD, Legro RS, Dunia A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 91: 492–497, 2006.

ABDOMINAL OBESITY AND INSULIN RESISTANCE

GRANTS
This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases Grants DK-58037 and DK-66369. J. Flowers was supported by the Nutritional Sciences Departmental Predoctoral Training Grant DK-07665-11.


54. Muoio DM, Dohm GL, Fiedorek FT Jr, Tapscott EB, Coleman RA.


57. Newton MA, Kendzierski CM, Richmond CS, Blattner FR, Tsui KW.

58. Park KS, Rhee BD, Lee KU, Kim SY, Lee HK, Koh CS, Min HK.


